Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lamivudine
Drug ID BADD_D01242
Description A reverse transcriptase inhibitor and zalcitabine analog in which a sulfur atom replaces the 3' carbon of the pentose ring. It is used to treat Human Immunodeficiency Virus Type 1 (HIV-1) and hepatitis B (HBV).
Indications and Usage For the treatment of HIV infection and chronic hepatitis B (HBV).
Marketing Status approved; investigational
ATC Code J05AF05
DrugBank ID DB00709
KEGG ID D00353
MeSH ID D019259
PubChem ID 60825
TTD Drug ID D07TQV
NDC Product Code 65015-756; 49702-203; 60687-362; 53873-075; 49702-205; 69097-167; 42385-714; 52482-003; 70966-0036; 0173-0663; 65862-055; 60505-3252; 65862-026; 69097-166; 53873-073; 55773-0589; 68554-0043; 31722-001; 49702-204; 64380-710; 68554-0016; 31722-752; 31722-754; 50742-624; 60687-720; 64380-711; 68180-602; 53104-7677; 70159-001; 31722-753; 54838-566; 57237-274; 60429-354; 66993-478; 68180-603; 53104-7538; 65015-701; 67835-0017; 60505-3250; 0904-6583; 53873-074; 65862-577; 33342-001; 0173-0662; 60505-3251; 65862-259; 65862-025; 82245-0204; 33342-002; 50742-623; 60429-353
UNII 2T8Q726O95
Synonyms Lamivudine | 3TC | 2',3'-Dideoxy-3'-thiacytidine | 2',3' Dideoxy 3' thiacytidine | Epivir | Lamivudine, (2S-cis)-Isomer | BCH-189 | BCH 189 | BCH189 | GR-109714X | GR109714X
Chemical Information
Molecular Formula C8H11N3O3S
CAS Registry Number 134678-17-4
SMILES C1C(OC(S1)CO)N2C=CC(=NC2=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hyperaesthesia23.03.03.080; 17.02.06.004--Not Available
Hypercholesterolaemia14.08.01.001--Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.001012%
Hyperhidrosis08.01.03.028; 23.02.03.004--
Hyperlactacidaemia14.01.01.006--Not Available
Hyperparathyroidism14.04.01.020; 05.04.01.0010.001012%
Hyperphosphataemia14.04.03.0070.002530%
Hypersensitivity10.01.03.003--
Hypertriglyceridaemia14.08.02.0010.001012%
Hypoaesthesia23.03.03.081; 17.02.06.0230.004250%Not Available
Hypocalcaemia14.04.01.0040.002024%
Hypoglycaemia14.06.03.001; 05.06.03.001--
Hypophosphataemia14.04.03.0010.002024%
Hypotension24.06.03.002--
Hypouricaemia14.09.01.0060.001012%Not Available
Hypoxia22.02.02.003--
Immune system disorder10.02.01.001--Not Available
Impaired healing08.03.02.0010.001012%Not Available
Infection11.01.08.002--Not Available
Influenza11.05.03.001; 22.07.02.001--Not Available
Injury12.01.08.004--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Insulin resistance14.06.02.003; 05.06.02.003--Not Available
Intentional self-injury19.12.01.002; 12.01.08.0360.002024%Not Available
Jaundice01.06.04.004; 23.03.03.030; 09.01.01.004--Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.001012%Not Available
Kyphosis15.10.04.0020.001012%
Lactic acidosis14.01.01.002--Not Available
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.002530%
Leukopenia01.02.02.001--Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 13 Pages